Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct 5;118(40):e2115221118.
doi: 10.1073/pnas.2115221118.

Choroid plexus volumetrics and brain inflammation in multiple sclerosis

Navid Manouchehri  1 , Olaf Stüve  2   3
Affiliations
Comment

Choroid plexus volumetrics and brain inflammation in multiple sclerosis

Navid Manouchehri et al. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interest statement: O.S. serves on the editorial boards of Therapeutic Advances in Neurological Disorders; has served on data monitoring committees for Genentech-Roche, Pfizer, Novartis, and TG Therapeutics without monetary compensation; has advised EMD Serono, Celgene, Genentech, TG Therapeutics, and Genzyme; and currently receives grant support from EMD Serono and Exalys.

Figures

Fig. 1.
Fig. 1.
The association of ChP volume with MS cumulative disease burden and treatment responses. The vast majority of patients who are diagnosed with MS have a relapsing remitting disease course. These patients experience clinical relapses and accumulate new lesions on brain MRI, two events that are often termed “disease activity” and, for the purpose of this illustration, “cumulative disease burden.” All currently approved DMT for MS reduce this cumulative disease burden. In the study by Fleischer et al. (8) there was a positive correlation between ChP volume and cumulative disease burden. Furthermore, the authors show that, despite a positive correlation between disease duration and ChP volume in treatment-naïve patients, treatment with DMF was not a predictor for ChP volume attenuation in follow-up assessments, whereas treatment with natalizumab was. Natalizumab is a humanized mAb that prevents the interaction of α4-integrin on leukocytes with its ligands on the BBB and within the extracellular matrix, reducing the adhesion and diapedesis into the brain. In contrast, DMF has no known direct effect of leukocyte migration across the BBB. This observation supports the assumption that ChP volume may be an imaging correlate of immune cell trafficking into the CNS rather than a mere readout of clinical improvement or treatment responses. Eventually, many MS patients no longer have clinical relapses, and they transition to a disease phenotype called SPMS. In patients with SPMS, currently approved DMT are no longer effective, including natalizumab. This suggest that 1) leukocyte traffic into the CNS no longer occurs through the ChP in patients with SPMS, 2) the composition of leukocytes changes at that disease stage, or 3) adhesion molecules other than α4-integrin are utilized for adhesion and diapedesis by those leukocytes in SPMS. This may further suggest that ChP volumetrics would no longer be a good imaging marker in SPMS. Perhaps most importantly, changes in ChP volume dynamics may serve as a marker of transition from RRMS to SPMS, a meaningful biological event for which there is currently no biomarker.
See this image and copyright information in PMC

Comment on

  • Translational value of choroid plexus imaging for tracking neuroinflammation in mice and humans.
    Fleischer V, Gonzalez-Escamilla G, Ciolac D, Albrecht P, Küry P, Gruchot J, Dietrich M, Hecker C, Müntefering T, Bock S, Oshaghi M, Radetz A, Cerina M, Krämer J, Wachsmuth L, Faber C, Lassmann H, Ruck T, Meuth SG, Muthuraman M, Groppa S. Fleischer V, et al. Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):e2025000118. doi: 10.1073/pnas.2025000118. Proc Natl Acad Sci U S A. 2021. PMID: 34479997 Free PMC article.

References

    1. Milo R., Korczyn A. D., Manouchehri N., Stuve O., The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis. Mult. Scler. 26, 876–886 (2019). - PubMed
    1. Ransohoff R. M., Schafer D., Vincent A., Blachère N. E., Bar-Or A., Neuroinflammation: Ways in which the immune system affects the brain. Neurotherapeutics 12, 896–909 (2015). - PMC - PubMed
    1. Yednock T. A., et al. ., Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356, 63–66 (1992). - PubMed
    1. Stüve O., et al. ., Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59, 743–747 (2006). - PubMed
    1. del Pilar Martin M., et al. ., Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch. Neurol. 65, 1596–1603 (2008). - PubMed

Publication types